CASE REPORT

HEMOPHAGOCYTIC SYNDROME ASSOCIATED WITH HEPATITIS A: CASE REPORT AND LITERATURE REVIEW

Felipe Francisco TUON(1), Virginia Soares GOMES(1), Valdir Sabbaga AMATO(2), Maria Esther GRAF(1), Guilherme Henrique Hencklain FONSECA(3), Carolina LAZARI(1) & Antonio Carlos NICODEMO(1)

SUMMARY

Virus-Associated Hemophagocytic Syndrome (VAHS) is a severe hematological disorder related to some viral infections. It is an illness characterized by persistent fever, pancytopenia, splenomegaly, hyperferritinemia and, the most important, hemophagocytosis observed in the bone marrow, liver and/or lymph nodes. VAHS associated with hepatitis A virus infection is rarely described, despite the high incidence of this viral infection in the population in general. There is no consensus in the literature regarding the optimal treatment of VAHS. In this article the clinical features, presumed pathogenesis, diagnostic criteria and treatment of VAHS are discussed, including description of cases of VAHS related to hepatitis A virus infection found in the medical literature.

KEYWORDS: Hemophagocytic syndrome; Hemophagocytosis; Viral-associated hemophagocytic syndrome; Hepatitis A virus; Intravenous immunoglobulin; Thrombocytopenia; Pancytopenia.

INTRODUCTION

Virus-Associated Hemophagocytic Syndrome (VAHS) is a severe hematological disorder related to some viral infections. Among these viral infections, the most likely to be associated with VAHS are Epstein-Barr virus, cytomegalovirus, human herpesvirus type 6 (HHV-6) and HHV-8. Nevertheless, some reports have described the association with human immunodeficiency virus (HIV), adenovirus, coxsackie virus, measles, dengue, rubella, parvovirus B19, herpes simplex virus and varicella zoster virus. Moreover, some cases of hemophagocytic syndrome have been reported in bacterial and protozoan infections.

VAHS was described by RISDALL et al. in 1979. He associated some hematological disorders with systemic viral infections in immunosuppressed patients which had clinical criteria of hemophagocytic syndrome. These diagnostic criteria were later reviewed by IMASHUKU and include persistent high fever, peripheral blood cytopenia (two or more series), hyperferritinemia, hyperlipidemia, and hemophagocytosis in the bone marrow (hemophagocytic cell ratio over 3%), spleen and/or lymph nodes. All these diagnostic criteria should be present in a patient with an active viral infection to confirm the diagnosis of VAHS.

Hemophagocytic syndrome associated with hepatitis A virus infection is rarely described, despite the high incidence of this infection in the population in general. There are only 12 cases reported in the medical literature.

The purpose of this manuscript is to describe a case of hepatitis A virus (HAV) infection, which developed into a VAHS and to review the literature on this matter.

CASE REPORT

A 24-year-old woman was hospitalized for the first time on October 15, 2006, complaining of nausea, vomiting, myalgia, jaundice, asthenia and fever. A diagnosis of acute hepatitis A was established based on the presence of specific IgM antibody anti-HAV. She was discharged from the hospital in better conditions. Thirty days later, all signs except jaundice were improved and she was admitted to another hospital with a diagnosis of severe anemia. Four blood units were transfused. After ten days she became febrile again and was admitted at the Hospital das Clinicas of University of São Paulo, Medical School.

The patient had presented severe jaundice and hepatosplenomegaly. Initial and further laboratory data are described in Table 1. Serology testing for toxoplasmosis, cytomegalovirus, rubella, EBV, hepatitis B and C, HIV and HTLV I/II were negative. Autoimmune hepatitis

---

(1) Department of Infectious and Parasitic Diseases, University of São Paulo Medical School, São Paulo, SP, Brazil.
(2) Infectious and Parasitic Diseases Clinic, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil.
(3) Department of Hematology, University of São Paulo Medical School, São Paulo, SP, Brazil.
Correspondence to: Dr. Antonio Carlos Nicodemo, Rua Barata Ribeiro, 414, Conjunto 104, 01308-000 São Paulo, SP, Brazil. Tel.: +55 11 32144251, Fax: +55 11 32591318. E-mail: ac_nicodemo@uol.com.br
antibodies were absent and the presence of IgM antibodies for hepatitis A was confirmed.

Ten days after admission, the patient still had fever and several blood units were required due to persistent severe anemia. A bone marrow aspiration was performed and hemophagocytosis was then diagnosed. Intravenous human immunoglobulin (IVIG) 400 mg/kg/day was prescribed for five days. After that, she did not require any further blood transfusion (Fig. 1). Despite the increased hemoglobin level, the patient developed a neutropenia (600 cells/mm³) which was successfully treated with G-CSF for three days. Three weeks later the patient was discharged without any complaints. She was in good health at the one year of follow-up.

**DISCUSSION**

The case here described has complied with all diagnostic criteria and, as far as we know, it is the first case of hemophagocytic syndrome associated with HAV infection in the Americas. Previous publications came from Japan, Taiwan and one case from England, totaling twelve cases related to VAHS and HAV infection. These manuscripts were found in the medical literature online on the LILACS, EMBASE, Web of Science and MEDLINE databases, including references from selected studies and case series of VAHS. Regarding these cases, some epidemiological and laboratorial findings are described in Table 2. Unfortunately, we were unable to describe three cases because they were published in Japanese language.

Leukocyte count is either normal or slightly low in the HAV infection and fever, in particular, rarely persists through the icteric phase, unless in atypical cases or if complication occurred. Hyperferritinemia is described in HAV infection, but not higher than 5,000 ng/mL. Hypertriglyceridemia can occur in several infectious diseases, including viral infections, but the levels usually do not exceed 500 mg/dL. Nevertheless, all previous clinical and laboratory features are uncommon in a later phase of HAV infection. These findings and hemophagocytosis in the bone marrow confirmed the diagnosis of VAHS in the case reported here.

**Table 1**

<table>
<thead>
<tr>
<th>Laboratory finding</th>
<th>25/Oct.</th>
<th>16/Nov.</th>
<th>4/Dec.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/L)</td>
<td>6</td>
<td>9.5</td>
<td>9.2</td>
</tr>
<tr>
<td>Leukocytes (cells/µL)</td>
<td>10,190</td>
<td>4,570</td>
<td>4,311</td>
</tr>
<tr>
<td>Platelets (no. x 10⁹/µL)</td>
<td>307</td>
<td>132</td>
<td>183</td>
</tr>
<tr>
<td>Direct bilirubin (mg/dL)</td>
<td>24.5</td>
<td>6.45</td>
<td>0.8</td>
</tr>
<tr>
<td>Indirect bilirubin (mg/dL)</td>
<td>6.43</td>
<td>1.33</td>
<td>0.7</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>451</td>
<td>112</td>
<td>71</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>350</td>
<td>116</td>
<td>97</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>125,340</td>
<td>16,780</td>
<td>6,542</td>
</tr>
<tr>
<td>Reticulocytes (%)</td>
<td>0.22</td>
<td>8.12</td>
<td>5.22</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>555</td>
<td>-</td>
<td>212</td>
</tr>
<tr>
<td>C-reactive Protein (mg/L)</td>
<td>66</td>
<td>24</td>
<td>11</td>
</tr>
<tr>
<td>Lactate dehydrogenase (U/L)</td>
<td>5,679</td>
<td>1,356</td>
<td>632</td>
</tr>
</tbody>
</table>

**Fig. 1** - Level of hemoglobin following treatment of VAHS and HAV.

**Table 2**

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Country</th>
<th>Ref</th>
<th>Age/ gender</th>
<th>Comorbidities</th>
<th>Leukocytes cells/µL</th>
<th>Hb (g/L)</th>
<th>Platelets no. x10⁹/µL</th>
<th>Date of cytopenia (after begin symptoms)</th>
<th>ALT IU/L</th>
<th>Total bilirubin mg/L</th>
<th>LDH IU/L</th>
<th>Ferritin ng/mL</th>
<th>Bone marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuon 2006</td>
<td>Brazil</td>
<td>24/F</td>
<td>None</td>
<td>10,190</td>
<td>6</td>
<td>307</td>
<td>60 days</td>
<td>10 days</td>
<td>340</td>
<td>5,679</td>
<td>30.9</td>
<td>125,340</td>
<td>+</td>
</tr>
<tr>
<td>Watanabe 2002</td>
<td>Japan</td>
<td>45/M</td>
<td>None</td>
<td>2,000</td>
<td>18.1</td>
<td>54</td>
<td>7 days</td>
<td>6,210</td>
<td>3.5</td>
<td>15,600</td>
<td>1,298</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Watanabe 2002</td>
<td>Japan</td>
<td>41/M</td>
<td>HCV</td>
<td>3,700</td>
<td>16.9</td>
<td>88</td>
<td>7 days</td>
<td>2,661</td>
<td>3.0</td>
<td>2,882</td>
<td>5,801</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tai 2005</td>
<td>Taiwan</td>
<td>32/M</td>
<td>None</td>
<td>2,140</td>
<td>13.0</td>
<td>114</td>
<td>3 days</td>
<td>1,579</td>
<td>3.6</td>
<td>698</td>
<td>1,002</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Wu 1995</td>
<td>Taiwan</td>
<td>23/M</td>
<td>HCV</td>
<td>7,800</td>
<td>4.2</td>
<td>40</td>
<td>14 days</td>
<td>355</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Onaga 2000</td>
<td>Japan</td>
<td>19/F</td>
<td>None</td>
<td>2,800</td>
<td>14.9</td>
<td>97</td>
<td>4 days</td>
<td>11,510</td>
<td>4.0</td>
<td>20,210</td>
<td>66,096</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kyoda 1998</td>
<td>Japan</td>
<td>40/M</td>
<td>None</td>
<td>5,800</td>
<td>15.9</td>
<td>37</td>
<td>admission</td>
<td>2,000</td>
<td>1.6</td>
<td>3,482</td>
<td>4,652</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>McPeake 1993</td>
<td>England</td>
<td>20/F</td>
<td>Still's disease</td>
<td>2,900</td>
<td>6.9</td>
<td>18</td>
<td>&gt; 6 days</td>
<td>119</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Kondo 1995</td>
<td>Japan</td>
<td>49/F</td>
<td>None</td>
<td>0,500</td>
<td>5.9</td>
<td>32</td>
<td>12 days</td>
<td>600</td>
<td>17</td>
<td>800</td>
<td>?</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ishii 2002</td>
<td>Japan</td>
<td>37/M</td>
<td>Alcohol abuse</td>
<td>6,000</td>
<td>13.8</td>
<td>10</td>
<td>21 days</td>
<td>Normal</td>
<td>30</td>
<td>Normal</td>
<td>?</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

(Ref - reference; Hb - hemoglobin; ALT - alanine aminotransferase; LDH - lactate dehydrogenase; HCV - hepatitis C virus)
Thrombocytopenia is the most common cytopenia in VAHS with HAV infection, followed by leucopenia. Only one case presented anemia in the literature reviewed. Some previous reports describe aplastic anemia or pure red cell aplasia related to hepatitis A14,43. These and other extrahepatic manifestations of HAV infection may be more common in patients who have protracted disease, such as relapsing or cholestatic hepatitis17,28. Cholestatic form of HAV infection is usually characterized by marked jaundice, pruritus, fever, weight loss and diarrhea. Biochemical and serologic abnormalities typically show high levels of serum bilirubin and alkaline phosphatase, elevated serum cholesterol, mild elevation of serum aminotransferases and often show maintenance of the anti-HAV IgM. The symptoms and signs may last for three months or more before complete recovery. This scenario is similar to the case reported herein.

Neutropenia is found in these patients and it is a risk factor of infections. Recent reports support the safety of Granulocyte-Colony Stimulating Factor (G-CSF) in patients with VAHS and severe neutropenia12,44,45. M-CSF is described as a trigger to the macrophage Stimulating Factor (G-CSF) in patients with VAHS and severe infections. Recent reports support the safety of Granulocyte-Colony Stimulating Factor (G-CSF) in patients with VAHS and severe infections. The possibility of G-CSF to increase the macrophage activation is not confirmed and it seems a useful drug to be used in patients with neutropenia due to VAHS.

The physiopathology of VAHS is established in the phagocytosis of blood cells precursors by macrophages22,22. (Fig. 2). KEREVEUR et al. described increasing expression of MHC class I and II molecules and increasing Macrophage-Colony Stimulating Factor (M-CSF) receptor expression in the macrophages20. Phagocytosis of platelets may be enhanced due to the presence of antiplatelet immunoglobulin G. Nevertheless, WATANABE et al. verified the presence of phagocytosis of platelets in the bone marrow46. Exaggerated activation of this group of cells may be due to high levels of activated cytokines, mainly of the inflammatory pattern. High levels of interferon-γ, interleukin-2 receptor, tumor necrosis factor-α, interleukin-1 and interleukin-6 have been demonstrated. This suggests that these cytokines produced by the T-helper cells promote macrophages activation15. The mechanism of abnormal cytokines production by these “hyperactivated” T lymphocytes remains unclear. Some authors explain this sustained activation by the persistence of antigens released by the trigger infection. The maintenance of antigen expression can be an innate immune defect found in natural killer cells46. Sometimes these cells can not destroy the infected cell by inducing apoptosis due to defect in the production of perforins or granzyme13,28. In the case described herein, the persistent cholestasis of the HAV infection could support this concept41.

The prognosis of the VAHS is mainly based in the severity and duration of the cytopenias. Long-term neutropenia increases the risk of severe infections, including gram-positive bacteria, such as S. aureus. Thrombocytopenia should be cautiously observed because of the possibility of spontaneous bleeding, which can occur in the central nervous system as a fatal outcome. Anemia is a risk factor for infections and can promote organ dysfunctions, such as heart failure and tissue hypoxia. Despite of cytopenias, some cases of VAHS developed disseminated intravascular coagulation and fatal organic dysfunction due to severe sepsis, contributing to the mortality of more than 40% in the largest series9.

The treatment of VAHS is not well defined because there are no controlled studies, once this disease is not common46. The supportive therapy consists of correcting the severe cytopenias and treating the causal infection.

The specific action of IVIG in the treatment of VAHS is not well-know26. LARROCHE et al. in France evaluated nine cases of VAHS treated with IVIG and concluded that the treatment was effective and reduced the time of hemophagocytosis25. However, more studies are necessary to verify the real efficacy of IVIG in the treatment of VAHS.

Some authors consider the immunosuppressive therapy a base to control hemophagocytosis. Although steroids have been commonly used in the treatment of VAHS, several reports showed failure45. Pulse therapy with steroid has showed improvement in some reports1. Plasmapheresis may be an alternative therapy in order to improve symptoms and laboratory abnormalities in the VAHS. Some reports have been successfully treated, including some cases after high doses of corticoid therapy29.

More studies are necessary in order to clarify the physiopathology and the immune mechanisms involved in this life-threatening disease.

**Fig. 2** - Schema of viral associated hemophagocytic syndrome. (NK - Natural killer cell; CD4+TL - Lymphocyte T CD4+; CD8+TL - Lymphocyte T CD8+; MO - Macrophage; IL-1 - Interleukin-1; IL-2 - Interleukin-2; IFN-γ - Interferon gamma; TNF-α - Tumor necrosis factor alpha.)

**RESUMO**

Síndrome hemofagocitária associada com hepatite A: relato de caso e revisão da literatura

A síndrome hemofagocitária associada a vírus é uma doença hematológica grave relacionada com algumas síndromes virais. É doença caracterizada por febre persistente, pancitopenia, esplenomegalia, hiperferritinemia e hemofagocitose na medula óssea, fígado e/ou linfonodos. A síndrome hemofagocitária associada ao vírus da hepatite A é raramente descrita, apesar da alta incidência desta infecção viral na população como um todo. Não existem consensos na literatura a respeito do tratamento desta morbidade. Neste artigo, os aspectos clínicos, patogênese, critérios diagnósticos e tratamento da síndrome hemofagocitária associada a vírus, incluindo a descrição de casos publicados da síndrome associada ao vírus da hepatite A.
ACKNOWLEDGEMENTS

We thank Mariana Pinheiro by the clinical assistance. We thank Vivian Iida da Silva, Alan Brito Neves, Helena Petta, André Machado, André Siqueira Machado, Silvia Goulart, Juliana Yamashiro, Luciana Campos, Margarete Vicentine and Hermes Higashino by the clinical and laboratory assistance.

REFERENCES


Received: 14 August 2007
Accepted: 2 January 2008